Trial Profile
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms I-CURE-1
- 30 Apr 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 30 Apr 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.
- 22 Apr 2019 Status changed from suspended to recruiting.